Anavex Life Sciences Corp (AVXL)

Etorro trading 970x250
Anavex Life Sciences Corp (AVXL) Logo

About Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer’s disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson’s disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company’s drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials to treat Alzheimer’s and Parkinson’s diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson’s, and Alzheimer’s diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company is based in New York, New York. Address: 51 West 52nd Street, New York, NY, United States, 10019

Anavex Life Sciences Corp News and around…

Latest news about Anavex Life Sciences Corp (AVXL) common stock and company :

First Week of March 4th Options Trading For Anavex Life Sciences (AVXL)
18 Jan, 2022 FinancialContent

Investors in Anavex Life Sciences Corp (AVXL) saw new options begin trading this week, for the March 4th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AVXL options chain for the new March 4th contracts and identified one put and one call contract of particular interest.

Noteworthy Friday Option Activity: TTD, AVXL, PACK
14 Jan, 2022 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in The Trade Desk Inc (TTD), where a total volume of 27,984 contracts has been traded thus far today, a contract volume which is representative of approximately 2.8 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 68.1% of TTD's average daily trading volume over the past month, of 4.1 million shares..

Investors Financial Group, LLC Buys USHG Acquisition Corp, Daktronics Inc, Weber Inc, Sells MP ...
14 Jan, 2022 Yahoo! Finance

Investment company Investors Financial Group, LLC (Current Portfolio) buys USHG Acquisition Corp, Daktronics Inc, Weber Inc, Verizon Communications Inc, Boeing Co, sells MP Materials Corp, Hyzon Motors Inc, JPMorgan Chase.

12 Health Care Stocks Moving In Friday's Pre-Market Session
14 Jan, 2022 FinancialContent

Gainers Molecular Partners (NASDAQ:MOLN) shares moved upwards by 11.9% to $31.66 during Friday's pre-market session. ...

First Week of February 25th Options Trading For Anavex Life Sciences (AVXL)
10 Jan, 2022 FinancialContent

Investors in Anavex Life Sciences Corp (AVXL) saw new options begin trading this week, for the February 25th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AVXL options chain for the new February 25th contracts and identified one put and one call contract of particular interest.

Anavex Life's Neurodegenerative Disease Candidate Meets Primary Endpoint In Early-Stage Study
10 Jan, 2022 FinancialContent

Anavex Life Sciences Corp(NASDAQ: AVXL)announced topline resultsfrom its Phase 1 trial of ANAVEX3-71 in development ...

Anavex Life Sciences Reports Positive Results from Phase 1 Clinical Trial of ANAVEX®3-71
10 Jan, 2022 Yahoo! Finance

Study reached primary and secondary endpoints of safety, respectively ANAVEX®3-71 well tolerated as oral administration in all dose cohorts No serious adverse events or dose-limiting toxicities observed Data provide early clinical proof of ANAVEX®3-71 having same pharmacokinetics in both gender and no food effect Company to host a webcast today at 8:30 a.m. ET NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage bioph

Noteworthy Thursday Option Activity: PEGA, AVXL, LYV
06 Jan, 2022 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Pegasystems Inc (PEGA), where a total of 1,750 contracts have traded so far, representing approximately 175,000 underlying shares. That amounts to about 45.7% of PEGA's average daily trading volume over the past month of 383,000 shares..

Anavex Life Sciences Promotes Walter E Kaufmann, M.D. to Chief Scientific Officer and Appoints Edward R Hammond, M.D., M.P.H., Ph.D., as Chief Medical Officer
06 Jan, 2022 Yahoo! Finance

NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that Walter E Kaufmann, M.D. has been promoted to Chief Scientific Officer and Edward R Hammond, M.

Anavex Life Sciences to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference
05 Jan, 2022 Yahoo! Finance

NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at

Interesting AVXL Put And Call Options For February 11th
03 Jan, 2022 FinancialContent

Investors in Anavex Life Sciences Corp (AVXL) saw new options become available this week, for the February 11th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AVXL options chain for the new February 11th contracts and identified one put and one call contract of particular interest.

Analysts Expect 11% Gains Ahead For VHT
30 Dec, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Health Care ETF (VHT), we found that the implied analyst target price for the ETF based upon its underlying holdings is $297.14 per unit.

Notable Wednesday Option Activity: COOP, AVXL, DASH
29 Dec, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Mr Cooper Group Inc (COOP), where a total volume of 5,275 contracts has been traded thus far today, a contract volume which is representative of approximately 527,500 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 48% of COOP's average daily trading volume over the past month, of 1.1 million shares..

Is the Options Market Predicting a Spike in Anavex (AVXL) Stock?
29 Dec, 2021 Yahoo! Finance

Investors need to pay close attention to Anavex (AVXL) stock based on the movements in the options market lately.

AVXL Crosses Below Key Moving Average Level
28 Dec, 2021 FinancialContent

In trading on Tuesday, shares of Anavex Life Sciences Corp (AVXL) crossed below their 200 day moving average of $17.73, changing hands as low as $17.68 per share. Anavex Life Sciences Corp shares are currently trading down about 7.2% on the day..

The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus
26 Dec, 2021 FinancialContent

Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts, and COVID-19 treatment and vaccine developments dictating sentiment. Here are the key biopharma catalysts for the unfolding week.

The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year
26 Dec, 2021 FinancialContent

Biopharma stocks eked out modest gains in the week endingDec. 23, with regulatory decisions, clinical readouts and COVID-19 ...

Anavex Life Sciences to Present at 40th Annual J.P. Morgan Healthcare Conference
14 Dec, 2021 Yahoo! Finance

Thursday, January 13, 2022 at 8:15 am Pacific Time / 11:15 am Eastern TimeNEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that its President and Chi

First Week of January 2022 Options Trading For Anavex Life Sciences (AVXL)
10 Dec, 2021 FinancialContent

Investors in Anavex Life Sciences Corp (AVXL) saw new options become available this week, for the January 2022 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AVXL options chain for the new January 2022 contracts and identified one put and one call contract of particular interest.

Anavex Life Sciences Corp. (NASDAQ:AVXL): Is Breakeven Near?
09 Dec, 2021 Yahoo! Finance

With the business potentially at an important milestone, we thought we'd take a closer look at Anavex Life Sciences...

Is Longeveron a Good Biotech Stock to Buy?
05 Dec, 2021 FinancialContent

Stem cell therapies are back in vogue, at least for this Miami-based biotechnology company.

Noteworthy Thursday Option Activity: AVXL, GRWG, EXPE
02 Dec, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Anavex Life Sciences Corp (AVXL), where a total volume of 3,964 contracts has been traded thus far today, a contract volume which is representative of approximately 396,400 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 42.8% of AVXL's average daily trading volume over the past month, of 926,740 shares..

Anavex Life Sciences (AVXL) Q4 2021 Earnings Call Transcript
02 Dec, 2021 FinancialContent

AVXL earnings call for the period ending September 30, 2021.

Anavex Life Sciences to Present at the 4th Annual Evercore ISI HealthCONx Conference
29 Nov, 2021 Yahoo! Finance

NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that its President and Chief Executive Officer, Christopher U. Missling, PhD, is scheduled to partic

12 Health Care Stocks Moving In Wednesday's After-Market Session
24 Nov, 2021 FinancialContent

Gainers iSpecimen (NASDAQ:ISPC) shares increased by 40.19% to $14.3 during Wednesday's after-market session. At the close, ...

The Daily Biotech Pulse: Kura's Blood Cancer Drug Study Gets Partial Clinical Hold, Takeda FDA Nod, Puma Breast Cancer Treatment Gets Patent Extension
24 Nov, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Puma Biotech Announces ...

Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Year End Financial Results
24 Nov, 2021 Yahoo! Finance

Webcast and Conference Call Today at 4:30 p.m. Eastern TimeNEW YORK, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal year ende

Earnings Scheduled For November 24, 2021
24 Nov, 2021 FinancialContent

Companies Reporting Before The Bell • Centogene (NASDAQ:CNTG) is likely to report quarterly loss at $0.55 per share on ...

Noteworthy Tuesday Option Activity: AVXL, JWN, NEE
23 Nov, 2021 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Anavex Life Sciences Corp (AVXL), where a total of 6,483 contracts have traded so far, representing approximately 648,300 underlying shares. That amounts to about 86.2% of AVXL's average daily trading volume over the past month of 752,110 shares..

Earnings Outlook For Anavex Life Sciences
23 Nov, 2021 FinancialContent

Anavex Life Sciences (NASDAQ:AVXL) is set to give its latest quarterly earnings report on Wednesday, 2021-11-24. Here's what investors ...

Anavex Life Sciences Corp (AVXL) is a NASDAQ Common Stock listed in , ,

970x250